Should I buy or sell ProMIS Neurosciences stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProMIS Neurosciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PMN shares. View PMN analyst ratings or view top-rated stocks .

What is ProMIS Neurosciences' stock price target for 2024?

2 brokerages have issued 1-year price targets for ProMIS Neurosciences' stock. Their PMN share price targets range from $8.00 to $8.00. On average, they expect the company's share price to reach $8.00 in the next year. This suggests a possible upside of 534.9% from the stock's current price. View analysts price targets for PMN or view top-rated stocks among Wall Street analysts .

How have PMN shares performed in 2023?

ProMIS Neurosciences' stock was trading at $4.34 on January 1st, 2023. Since then, PMN shares have decreased by 71.0% and is now trading at $1.26. View the best growth stocks for 2023 here .

When is ProMIS Neurosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 13th 2024. View our PMN earnings forecast .

Who are ProMIS Neurosciences' major shareholders?

ProMIS Neurosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Affinity Asset Advisors LLC (3.10%).

How do I buy shares of ProMIS Neurosciences?

Shares of PMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

ProMIS Neurosciences Stock Price, News & Analysis (NASDAQ:PMN)

$1.26

+0.06 (+5.00%)

(As of 11/29/2023 ET)

Compare

Today's Range: $1.12
▼
$1.35
50-Day Range: $1.20
▼
$2.01
52-Week Range: $1.12
▼
$8.95

Volume: 12,705 shs
Average Volume: 112,362 shs
Market Capitalization: $23.80 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.00

ProMIS Neurosciences MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 534.9% Upside
$8.00 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.36) to ($1.08) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

623rd out of 949 stocks

Pharmaceutical Preparations Industry

292nd out of 431 stocks

3.5

Analyst's Opinion

Consensus Rating
ProMIS Neurosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.00, ProMIS Neurosciences has a forecasted upside of 534.9% from its current price of $1.26.
Amount of Analyst Coverage
ProMIS Neurosciences has only been the subject of 1 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for PMN.

0.0

Dividend Strength

Dividend Yield
ProMIS Neurosciences does not currently pay a dividend.
Dividend Growth
ProMIS Neurosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PMN.

3.3

News and Social Media Coverage

News Sentiment
ProMIS Neurosciences has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for ProMIS Neurosciences this week, compared to 0 articles on an average week.
MarketBeat Follows
Only 1 people have added ProMIS Neurosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ProMIS Neurosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
10.30% of the stock of ProMIS Neurosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 2.18% of the stock of ProMIS Neurosciences is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for ProMIS Neurosciences are expected to grow in the coming year, from ($1.36) to ($1.08) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ProMIS Neurosciences is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ProMIS Neurosciences is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ProMIS Neurosciences has a P/B Ratio of 3.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About ProMIS Neurosciences Stock (NASDAQ:PMN)

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

PMN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PMN Stock News Headlines

November 14, 2023 | msn.com

ProMIS Neurosciences GAAP EPS of -$0.19 beats by $0.14

September 6, 2023 | finance.yahoo.com

ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

November 30, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

August 22, 2023 | msn.com

ProMIS Neurosciences scales 31% on $20.4M private placement

August 21, 2023 | finance.yahoo.com

ProMIS Neurosciences Announces $20.4 Million Private Placement Financing

May 15, 2023 | finance.yahoo.com

ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights

May 6, 2023 | theglobeandmail.com

Closing Bell: Promis Neurosciences Inc down on Friday (PMN)

April 27, 2023 | theglobeandmail.com

Closing Bell: Promis Neurosciences Inc up on Thursday (PMN)

November 30, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

April 25, 2023 | finance.yahoo.com

Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer’s Disease

April 24, 2023 | finance.yahoo.com

ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual Meeting

April 19, 2023 | theglobeandmail.com

Closing Bell: Promis Neurosciences Inc up on Tuesday (PMN)

April 18, 2023 | theglobeandmail.com

Closing Bell: Promis Neurosciences Inc down on Monday (PMN)

April 15, 2023 | theglobeandmail.com

Closing Bell: Promis Neurosciences Inc up on Friday (PMN)

April 10, 2023 | proactiveinvestors.com

ProMIS Neurosciences submits IND application for Alzheimer's treatment

See More Headlines

Receive PMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProMIS Neurosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 11/29/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/13/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PMN
CUSIP: N/A
CIK: 1374339
Web: www.promisneurosciences.com
Phone: (416) 847-6898
Fax: N/A
Employees: 6
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.00
High Stock Price Target: $8.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +555.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.94)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-18,060,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -219.98%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.81
Quick Ratio: 1.81

Sales & Book Value

Annual Sales: $10,000.00
Price / Sales: 2,306.85
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.36 per share
Price / Book: 3.39

Miscellaneous

Outstanding Shares: 18,890,000
Free Float: 16,940,000
Market Cap: $23.07 million
Optionable: Not Optionable
Beta: 0.69

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Eugene Williams (Age 64)
Co-Founder & Chairman
Comp: $439.21k
Dr. Gail M. Farfel Ph.D. (Age 59)
CEO & Director
Comp: $177.23k
Dr. Neil R. Cashman M.D. (Age 71)
Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director
Comp: $333.8k
Mr. Gavin T. Malenfant (Age 59)
Chief Operating Officer
Comp: $413.49k
Mr. Daniel E. Geffken M.B.A. (Age 66)
Chief Financial Officer
Comp: $88.64k
Dr. Johanne Kaplan Ph.D. (Age 63)
Chief Development Officer
Comp: $259.12k
Dr. Ernest D. Bush Ph.D.
Head of Pharmacology/Toxicology & Senior Consultant
Dr. David Wishart Ph.D.
Chief Physics Officer
Mr. Dennis Chen Ph.D.
Head of Manufacturing & Senior Consultant
Dr. Larry Douglas Altstiel M.D. (Age 73)
Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

Affinity Asset Advisors LLC
Bought 265,958 shares on 11/15/2023
Ownership: 3.100%

View All Institutional Transactions

PMN Stock Analysis - Frequently Asked Questions

Should I buy or sell ProMIS Neurosciences stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProMIS Neurosciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PMN shares.
View PMN analyst ratings or view top-rated stocks.
What is ProMIS Neurosciences' stock price target for 2024?: 2 brokerages have issued 1-year price targets for ProMIS Neurosciences' stock. Their PMN share price targets range from $8.00 to $8.00. On average, they expect the company's share price to reach $8.00 in the next year. This suggests a possible upside of 534.9% from the stock's current price.
View analysts price targets for PMN or view top-rated stocks among Wall Street analysts.
How have PMN shares performed in 2023?: ProMIS Neurosciences' stock was trading at $4.34 on January 1st, 2023. Since then, PMN shares have decreased by 71.0% and is now trading at $1.26.
View the best growth stocks for 2023 here.
When is ProMIS Neurosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 13th 2024.
View our PMN earnings forecast.

Who are ProMIS Neurosciences' major shareholders?: ProMIS Neurosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Affinity Asset Advisors LLC (3.10%).
How do I buy shares of ProMIS Neurosciences?: Shares of PMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:PMN) was last updated on 11/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ProMIS Neurosciences Stock Price, News & Analysis (NASDAQ:PMN)

ProMIS Neurosciences MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About ProMIS Neurosciences Stock (NASDAQ:PMN)

PMN Stock Price History

PMN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

PMN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™